We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What pleased me was that there is no further extension to the work with Lilly and they are now discussing a licence agreement. Nothing negative about that.
Agree lunus, the wait continues as planned.
Because its pharma mate. Takes time and patience.
The dreaded RNS curse strikes again, why does anyone bother as all that happens is the SP goes down.
Its an interim results should not be any news of results or new agreements here. Are ppl this daft here?
Cash statement is really positive to me considering the extremely wide range of research this small company is in. And most of the research costs are on their collaborators, thats very important to see. Looks very promising to hold and buy these dips idiots are creating.
Not much point in posting that Rns did not say anything it would of been better not to list anything
Peel Hunt will test this down to 10p today.
Nothing in the RNS that is new.
Agreed - think we’ll be below 10 today as traders sell and the LTHs hold. Chance to top-up or just sit and hold.
Nothing new, no Boom statement.
Cash flow will be an issue at some point in 2021.
Unless seperate news comes later, I think a lot of traders may free up cash and sell
Well we have the Rns
Not exactly shattering brilliant but it's not negative
Confirmation of projects. Things close to the belt.
For sure burning cash. That is what Research companies do without revenue.
It will take one of the aforementioned projects to be licensed to set this company on a bet high projectile.
Just one and they have about 6.
SP wise- I have zero idea short term. I’d say it will stay same or a small drop leakage until one of the research areas comes to fruition.
Howver I know it’s a standard reSponse I’d top up.
I topped up 100k on Monday.
This so rises quickly on news.
We have 5 or 6 pieces of news and veg large global cod that will create huge interest and rises.
No brainier hold or hold and buy
I’m here for the big rises as MCAP low.
If a COVID test/ collaboration came out even in trial form this will go through the roof on sentiment.
And with out fail pumpkin with negative view FUN SPONGE
No revenues, a bit disappointing but it's fine.
Cash position is strong, may require additional funding in 2021.
CDX is commercial discussions and on track to schedule completion (1st December).
Feldmann believes we will still reach inflection point in 2020.
All in all quite strong update albeit brief.
Love this!!
The Board believes that the Company is well advanced on the planned development steps for its CDX antibodies, and will provide further updates to shareholders as we progress toward the completion of our collaboration with GlobalCo and enter pre-clinical development.
£83k for mice sales to...
Cheers, Vick.
I'm a longtime holder in Hemo. Bought most of it at 2p. But I'm not exactly an expert. I use the board to learn from those who know more. Thanks for the response.
Basically, everything is the same. But they confirm that lab work has concluded with Eli and they're talking about a licencing deal. That's all I needed to know from this. CAR-T they're very keen to push and keep mentioning the pace to clinical trials which is Bueno
They seriously need some incone;theyre burning cash imho
Very strong narrative. What's not to like. Shareholders can look forward to a very interesting 2nd period.
It will take a brave shareholder to sell right now, potential blockbuster news on a number of fronts could come anytime.
The Board remains very pleased with progress, in particular the rapid advances in the Company's new CAR-T project and its very significant partnership with the University of Pennsylvania that promise to accelerate the Company towards clinical trial stage. The finalisation of the CDX antibody research agreement with GlobalCo is also greatly anticipated, along with the outcome of commercial discussions with GlobalCo. The Company has been able to make strong progress across its main developments thanks to the exceptional productivity of its team of scientists. The Board believes that the Company is well advanced on the planned development steps that were described in the 2019 annual report and the goals set out for the use of funds raised this year, and will provide further updates to shareholders as the Company progresses. The Company looks forward to the future with confidence.
What are your thoughts guys?